[go: up one dir, main page]

NO923395L - Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener - Google Patents

Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener

Info

Publication number
NO923395L
NO923395L NO92923395A NO923395A NO923395L NO 923395 L NO923395 L NO 923395L NO 92923395 A NO92923395 A NO 92923395A NO 923395 A NO923395 A NO 923395A NO 923395 L NO923395 L NO 923395L
Authority
NO
Norway
Prior art keywords
oral administration
autoimmune diseases
reinforcement
down regulation
autoimmune disease
Prior art date
Application number
NO92923395A
Other languages
English (en)
Other versions
NO923395D0 (no
Inventor
Howard L Weiner
David A Hafler
Samia J Khoury
Original Assignee
Autoimmune Inc
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc, Brigham & Womens Hospital filed Critical Autoimmune Inc
Publication of NO923395L publication Critical patent/NO923395L/no
Publication of NO923395D0 publication Critical patent/NO923395D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåter for forhindring eller behandling av T- celleavhenglge autoimmune sykdommer omfattende oral administrering av (A) et middel valgt fra gruppen bestående av autoantigener, fragmenter eller analoger derav spesifikke for den autoimmune sykdommen, og (B) en synerglst som har egenskapen av å forsterke den supprimerende aktiviteten til midlet ved autoimmun sykdom, l mengder som er effektive for å behandle eller forhindre en T-celleavhengig autoimmur. sykdom, er beskrevet. Farmasøytiske formuleringer eller doserings- former for anvendelse i fremgangsmåtene er også beskrevet.
NO923395A 1990-03-02 1992-08-31 Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener NO923395D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773290A 1990-03-02 1990-03-02
PCT/US1991/001466 WO1991012816A1 (en) 1990-03-02 1991-03-04 Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens

Publications (2)

Publication Number Publication Date
NO923395L true NO923395L (no) 1992-08-31
NO923395D0 NO923395D0 (no) 1992-08-31

Family

ID=23936898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923395A NO923395D0 (no) 1990-03-02 1992-08-31 Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener

Country Status (13)

Country Link
EP (2) EP0594607B1 (no)
JP (1) JPH05508621A (no)
AT (1) ATE157257T1 (no)
AU (1) AU651097B2 (no)
BR (1) BR9106114A (no)
CA (1) CA2077340A1 (no)
DE (1) DE69127470T2 (no)
DK (1) DK0594607T3 (no)
ES (1) ES2107459T3 (no)
HU (2) HUT61896A (no)
IL (1) IL97446A (no)
NO (1) NO923395D0 (no)
WO (1) WO1991012816A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
CA2117492C (en) * 1992-02-28 2009-04-07 Howard L. Weiner Bystander suppression of autoimmune diseases
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
JPH09509135A (ja) * 1993-06-02 1997-09-16 ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ 免疫寛容の誘導における利用のためのクリプティックペプチド
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE69525544T2 (de) 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996040205A1 (en) * 1995-06-07 1996-12-19 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5840848A (en) * 1996-01-05 1998-11-24 Autoimmune, Inc. Method for preparation of type II collagen
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2410563C (en) 2000-05-24 2013-04-23 John M. Hallenbeck Methods for preventing strokes by inducing tolerance to e-selectin
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
JPS60149386A (ja) * 1984-01-17 1985-08-06 Dainippon Pharmaceut Co Ltd インタ−ロイキン１をコ−ドする伝令リボ核酸及びその調製法
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
DE19848246A1 (de) 1998-10-20 2000-04-27 Krauss Maffei Kunststofftech Thermoplastteil mit eingespritzter Elastomerdichtung
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors

Also Published As

Publication number Publication date
CA2077340A1 (en) 1991-09-03
BR9106114A (pt) 1993-03-09
DE69127470T2 (de) 1998-02-19
ES2107459T3 (es) 1997-12-01
EP0594607B1 (en) 1997-08-27
JPH05508621A (ja) 1993-12-02
EP0594607A4 (en) 1993-04-20
DK0594607T3 (da) 1998-04-14
WO1991012816A1 (en) 1991-09-05
ATE157257T1 (de) 1997-09-15
NO923395D0 (no) 1992-08-31
HU210813A9 (en) 1995-08-28
IL97446A0 (en) 1992-06-21
AU651097B2 (en) 1994-07-14
EP0782859A1 (en) 1997-07-09
IL97446A (en) 1996-03-31
HUT61896A (en) 1993-03-29
HU9202808D0 (en) 1992-12-28
DE69127470D1 (de) 1997-10-02
EP0594607A1 (en) 1994-05-04
AU7578991A (en) 1991-09-18

Similar Documents

Publication Publication Date Title
NO923395D0 (no) Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener
DK0552256T3 (da) Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin
PT627933E (pt) Supressao "bystander" de doencas autoimunes
IL99754A0 (en) Pharmaceutical composition for treatment of autoimmune diseases containing an autoantigen or a fragment or analogue thereof
IL96734A0 (en) Aerosol formulations of autoantigens
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
NL990012I2 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
ATE178793T1 (de) L-dopa ester-enthaltende zusammensetzung
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR880001292A (ko) 자가면역병 치료를 위한 브로모크립틴의 단독 요법
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
ATE58478T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
EP0612532A3 (en) Canine coronavirus vaccine from feline enteric coronavirus
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.